GlassScriptPhysician profile
Sunder Rao
NPI 1164497293
$109,908.97
in general payments reported to CMS, 2019-2025
48 companies · $8,697 in 2025
The $8,697 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $17K · 2021: $21K · 2022: $15K · 2023: $15K · 2024: $15K · 2025: $8,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $12K · Travel and Lodging: $1,820 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,555.00 |
| Food and Beverage | $12,249.83 |
| Travel and Lodging | $1,819.52 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61,374.97 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $16,639.35 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $5,104.14 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $3,347.02 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $2,970.89 | 2019-2025 | Andexxa, Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $2,549.86 | 2019-2025 | Leqvio |
| E.R. Squibb & Sons, L.L.C. | $2,254.89 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $2,235.90 | 2019-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $1,407.59 | 2019-2021 | |
| Novo Nordisk INC | $1,377.46 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Heartflow, INC. | $960.84 | 2022-2025 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $945.29 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $921.51 | 2019-2024 | Opsumit, Uptravi |
| Pfizer INC. | $815.27 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $760.43 | 2019-2025 | Lifevest |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $725.15 | 2020-2025 | Evkeeza, Praluent |
| Scpharmaceuticals INC. | $721.47 | 2023-2025 | |
| Amarin Pharma, INC. | $488.88 | 2019-2022 | |
| Cvrx, INC. | $471.06 | 2021-2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $381.84 | 2021-2025 | Verquvo, Winrevair |
| Boston Scientific Corporation | $329.44 | 2019-2025 | Watchman, Watchman Flx |
| Abbott Laboratories | $327.78 | 2019-2024 | Gallant |
| Vifor Pharma, INC. | $313.49 | 2019-2022 | |
| Esperion Therapeutics, INC. | $270.29 | 2020-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $216.74 | 2023-2024 | Inpefa |
| United Therapeutics Corporation | $204.13 | 2019-2025 | Orenitram, Remodulin, Tyvaso |
| Kiniksa Pharmaceuticals, LTD. | $170.31 | 2021-2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $164.44 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $162.23 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $161.28 | 2022-2023 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $160.01 | 2019-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $152.50 | 2025 | Optimizer |
| Irhythm Technologies, INC. | $127.00 | 2022 | |
| Abbvie INC. | $114.30 | 2022 | |
| Getinge USA Sales, LLC | $94.50 | 2021 | |
| Lundbeck LLC | $93.49 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $92.50 | 2024 | Xarelto |
| Daiichi Sankyo INC. | $79.96 | 2019-2024 | Injectafer |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Tactile Systems Technology INC | $47.48 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Altathera Pharmaceuticals LLC | $43.18 | 2023 | Sotalol Hydrochloride |
| Atricure, INC. | $25.88 | 2019 | |
| Ge Healthcare | $22.45 | 2023 | |
| Edwards Lifesciences Corporation | $18.84 | 2022 | |
| Gilead Sciences, INC. | $12.94 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunder Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.